Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corbus Pharmaceuticals Holdings (CRBP) Total Debt (2020 - 2024)

Corbus Pharmaceuticals Holdings has reported Total Debt over the past 4 years, most recently at $15.9 million for Q4 2023.

  • For Q4 2023, Total Debt fell 15.09% year-over-year to $15.9 million; the TTM value through Dec 2023 reached $15.9 million, down 15.09%, while the annual FY2023 figure was $15.9 million, 15.09% down from the prior year.
  • Total Debt for Q4 2023 was $15.9 million at Corbus Pharmaceuticals Holdings, up from $36868.0 in the prior quarter.
  • Over five years, Total Debt peaked at $19.3 million in Q3 2022 and troughed at $36868.0 in Q3 2023.
  • A 4-year average of $16.3 million and a median of $18.8 million in 2021 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: grew 3.17% in 2022 and later plummeted 99.81% in 2023.
  • Year by year, Total Debt stood at $18.8 million in 2020, then dropped by 0.51% to $18.7 million in 2021, then rose by 0.27% to $18.8 million in 2022, then decreased by 15.09% to $15.9 million in 2023.
  • Business Quant data shows Total Debt for CRBP at $15.9 million in Q4 2023, $36868.0 in Q3 2023, and $11.4 million in Q2 2023.